FRANCESCO GALIMI, MD PhD

Chief Medical Officer

fgalimi@gmail.com | linkedin.com/in/fgalimi

SUMMARY

- Experienced physician-scientist and physician-executive with a 30+ year career in medicine, both in academia and in the bio-pharmaceutical industry.
- Track record of leadership and management of cross-functional organizations, from preclinical research to registrational activities.
- Thirty+ years of experience in hematology and oncology R&D.
- Board certified in Medical Oncology in the EU.
- Extensive experience in medical teaching (25+ years).

EXPERIENCE OVERVIEW

Senior Vice President and Chief Medical Officer
2019-2024

Adicet Bio, Inc. Redwood City, CA

Member of the Executive Leadership Team, reporting directly to the Chief Executive Officer. Oversees the Company's portfolio of oncology and autoimmune cell therapy programs.

Global Program General Manager
2014-2019

Amgen, Inc. Thousand Oaks, CA

Responsible for the cross-functional strategy and execution of a portfolio of drug development programs, from pre-IND to late-stage development.

Head of Clinical Development
2013-2014

Onyx Pharmaceuticals, Inc. South San Francisco, CA

Responsible for leadership and management of the Clinical Development group.

Executive Medical Director
2011-2013

Novartis, Inc. San Diego, CA

Responsible for the early development strategy and execution of a portfolio of drug development programs.

Medical Director
2006-2011

Amgen, Inc. Thousand Oaks, CA

Design, conduct, and analysis of multiple global clinical trials across major indications in oncology therapeutics.

EDUCATION AND TRAINING

- M.D., Cum Laude, University of Torino — 1991
- Ph.D. in Human Oncology, University of Torino — 1995
- EU Board of Medical Oncology, University of Torino — 1999
- Fellow in Medical Oncology, Dept. of Biomedical Sciences, University of Torino — 1995-1999
- Postdoctoral Fellow, Salk Institute, La Jolla, CA — 1998-2003

Core Competencies

- Member of Executive Leadership Teams in private and public biotech companies.
- Broad and deep experience in bio-pharmaceutical R&D, across different therapeutic modalities (small molecules, antibodies, peptibodies, antibody-drug conjugates, oncolytic viral vectors, immunotherapy and cell therapy programs) in all phases of development.
- Superior leadership, interpersonal, and communication skills.
- Leadership of discovery projects resulting in successful identification of clinical candidates.
- Comprehensive experience in translational medicine in hematology, oncology and autoimmune disorders for small molecule, biologic, antibody-drug conjugate, immunotherapy and cell therapy programs.
- Design, execution, and analysis of global phase I-II-III clinical trials in malignant and non-malignant hematology, oncology and rheumatology therapeutics, including large phase III registrational studies.
- Leadership of complex development plans from early clinical to commercial and payor/access strategy.
- Implementation of companion diagnostic strategies for patient identification and pharmacodynamic biomarkers.
- US, EU, Eastern Europe, Japan and China regulatory interactions in multiple IND and NDA filing activities.

Languages

- English, Italian, French

Nationality

- Italian/American dual citizen

Table of Contents

PERSONAL INFORMATION

Contact Info

12930 Via Esperia
Del Mar, CA 92014, USA
fgalimi@gmail.com
+1 (805) 669-7278

Nationality

Italian/American dual citizen

EDUCATION

Medical Studies

1991	M.D., *Cum Laude*, University of Torino Medical School
1995	Ph.D. in Human Oncology, University of Torino Medical School
1999	Specialty Certification in Medical Oncology (EU Board of Medical Oncology), University of Torino Medical School

Postdoctoral Training

1995 – 1999	Fellow in Medical Oncology, Dept. of Biomedical Sciences, University of Torino Medical School, Torino, Italy
1998 – 2003	Postdoctoral Fellow, Dr. Inder Verma's Laboratory, The Salk Institute for Biological Studies, La Jolla, California

Languages

Native Italian speaker

1982	French, Diplôme de l'Alliance Française
1986	English, Cambridge Certificate of Proficiency in English, University of Cambridge (UK)

INDUSTRY EXPERIENCE

2019 – 2024 **Senior Vice President and Chief Medical Officer**

Adicet Bio, Inc. **Redwood City, CA**

Member of the Executive Leadership Team, reporting directly to the Chief Executive Officer.

Built the Company's clinical organization from the ground up to include Clinical Development, Medical Affairs, Translational Medicine, Regulatory, Biostatistics, Clinical Operations, Data Management, Program Management and Program Leadership.

Leading the development of the Company's portfolio of assets in hematology/oncology and rheumatology.

2015 – 2019 **Global Program General Manager**

Amgen, Inc. **Thousand Oaks, CA**

Reporting directly into CEO Staff, managed the cross-functional strategy and execution of a portfolio of immuno-oncology drug development programs, from pre-IND to late-stage. Accountable for both development strategy and global launch planning and execution.

Team lead for small molecule and immunotherapy programs, including AMG 176, AMG 387 (MCL1 inhibitors), oprozomib (proteasome inhibitor), AMG 420, AMG 701, AMG 424 (bispecific T-cell engagers).

2014 – 2015 **Head of Clinical Development**

Onyx Pharmaceuticals, Inc. **South San Francisco, CA**

Responsible for leadership and management of the Clinical Development group at Onyx (50+ staff members including MDs, PhDs, PharmDs, medical writers and administrative staff). Main focus was on carfilzomib and oprozomib (proteasome inhibitors).

2011 – 2014 **Executive Director, Oncology Translational Medicine**

Novartis, Inc. **San Diego, CA**

Key activities: responsible for the early development strategy and execution of a portfolio of small molecule, antibody-drug conjugate, and immunotherapy programs. Responsible for providing clinical input and organizational alignment to research teams at Novartis sites located on the West Coast of the US. Clinical lead for multiple small molecule and antibody-drug conjugate programs in phase I-II.

2007 – 2011 **Clinical Research Medical Director**

Amgen, Inc. **Thousand Oaks, CA**

Key activities: design, conduct, and analysis of multiple global clinical trials across major indications in oncology therapeutics.

Served as Medical Director for all the pro-apoptotic antibody clinical studies in the company's pipeline centered on the TRAIL agonists conatumumab and dulanermin. Served as Medical representative on regulatory interactions and filing activities.

Served as Medical Director on phase III registrational studies for small molecules (motesanib) and oncolytic viral vectors (talimogene laherparepvec).

Implemented innovative workflows for clinical data review in the context of medical/safety monitoring and database validation activities.

Managed complex global cross-functional teams through all stages of translational and clinical development.

2006 – 2007 **Early Development Team Leader**

Amgen, Inc. **Thousand Oaks, CA**

Key activities: lead early development teams, from clinical candidate identification to first-in-human studies. Main focus was on thrombopoietin agonists (romiplostim).

2004 – 2006 **Senior Scientist** (2004) and **Principal Scientist** (2005-2006)

Amgen, Inc. **Thousand Oaks, CA**

Key activities: lead a team of 6 through the inception and execution of a number of discovery research programs in oncology and hematology. Identified clinical candidates which moved to first-in-human. Supported the licensing department in evaluating external opportunities.

Patents

US 6,030,949	Macrophage stimulating protein for the treatment of pathologies of the nervous system.
US 2004/ 0235169 A1	Inducible expression of transfected genes.
US 7,981,425	Thrombopoietic compounds.
ITMI971248	Proteina stimolante i macrofagi come agente protettivo della tossicità renale indotta da farmaci.
EP0880971 B1	Macrophage stimulating protein for the treatment of pathologies of the nervous system.
WO2023102264A1	Treatment of B-cell malignancies.

Selected Regulatory Filings

Company	Program	Filing	Modality / Mechanism of Action	Indication	Role	Notes
Amgen	AMG 195	IND	peptibody; TPO agonist	immune trombocytopenic purpura	program lead	discontinued
Amgen	AMG 531 (romiplostim)	BLA	peptibody; TPO agonist	immune trombocytopenic purpura	team member	now approved as Nplate©
Amgen	AMG 655 (conatumumab)	IND/CTA	antibody; DR5 agonist	solid tumors	clinical lead	discontinued
Amgen	AMG 706 (motesanib)	NDA	small molecule; kinase inhibitor	non-small cell lung cancer	clinical lead of the registrational trial	NDA retracted
Amgen	AMG 176	IND	small molecule; mcl-1 inhibitor	AML; solid tumors	program lead	discontinued
Amgen	AMG 232	IND	small molecule; mdm-2 inhibitor	various cancer indications	program lead	outlicensed
Amgen	AMG 397	IND	small molecule; mcl-1 inhibitor	AML; solid tumors	program lead	discontinued
Amgen	AMG 224	IND	antibody-drug conjugate; anti-BCMA	multiple myeloma	program lead	discontinued
Novartis	LEE011 (ribociclib)	IND	small molecule; CDH4/6 inhibitor	breast cancer	clinical lead	now approved as Kisqali©
Novartis	LOP628	IND	antibody-drug conjugate; anti-cKit	gastrointestinal stromal tumors	clinical lead	discontinued

Amgen	talimogene laherparepvec	BLA	cytolytic herpesvirus	melanoma	clinical lead of the registrational trial	now approved as Imlygic©
Onyx	oprozomib	IND	small molecule; proteasome inhibitor	multiple myeloma	Head of Clinical Development and program lead	discontinued
Onyx	carfilzomib	NDA	small molecule; proteasome inhibitor	multiple myeloma	Head of Clinical Development	now approved as Kyprolis©
Amgen	AMG 420	IND/CTA	bispecific T-cell engager; BCMA x CD3	multiple myeloma	program lead	discontinued
Amgen	AMG 701	IND/CTA	bispecific T-cell engager; BCMA x CD3	multiple myeloma	program lead	discontinued
Amgen	AMG 424	IND	bispecific T-cell engager; CD38 x CD3	multiple myeloma	program lead	discontinued
Adicet Bio	ADI-001	IND	gamma delta allo-CART; anti-CD20	non-Hodgkin's lymphoma	Chief Medical Officer	phase 1/2
Adicet Bio	ADI-001	IND/CTA	gamma delta allo-CART; anti-CD20	systemic lupus erythematosus	Chief Medical Officer	phase 1/2
Adicet Bio	ADI-001	IND/CTA	gamma delta allo-CART; anti-CD20	systemic sclerosis	Chief Medical Officer	phase 1/2
Adicet Bio	ADI-001	IND/CTA	gamma delta allo-CART; anti-CD20	vasculitis	Chief Medical Officer	phase 1/2
Adicet Bio	ADI-270	IND/CTA	gamma delta allo-CART; anti-CD70	solid tumors; AML; MM	Chief Medical Officer	phase 1

ACADEMIC APPOINTMENTS

2019 – 2025	Adjunct Associate Professor of Histology, University of Sassari Medical School, Sassari, Italy
2006 – 2018	Associate Professor of Histology, University of Sassari Medical School, Sassari, Italy
1997 – 2005	Assistant Professor of Histology, University of Sassari Medical School, Sassari, Italy

Teaching and Mentoring Activities

1999 – present	Mentoring of M.S. and Ph.D. students interested in establishing a career in the pharma/biotech sector
2000 – 2018	Graduate Advisor, Ph.D. program in Molecular Biology and Biochemistry, University of Sassari
1999 – 2018	Course Director, Gene Therapy and Transfer, University of Sassari Medical School
1999 – 2018	Course Director, Histology and Embryology, University of Sassari Medical School
1997 – 1999	Lecturer, Histology and Embryology, University of Sassari Medical School

RESEARCH EXPERIENCE

2004 – 2006	Senior Scientist (2004) and Principal Scientist (2005-2006), Amgen (*discovery research*) Key activities: lead a team of 6 through the inception and execution of a portfolio of discovery research programs in oncology and hematology. Identified clinical candidates which moved to first-in-human
1998 – 2003	Postdoctoral Fellow, Dr. Inder Verma's Laboratory, The Salk Institute for Biological Studies, La Jolla, California Research focused on lentiviral-mediated gene transfer models of disease (*see Publications*)
1991 – 1999	PhD student and Fellow in Medical Oncology, Dept. of Biomedical Sciences, University of Torino Medical School, Torino, Italy Research focused on the biology of Hepatocyte Growth Factor (*see Publications*)

Fellowships and Awards

2000	Forbeck Foundation Scholar Award
1999 – 2002	José Carreras International Leukemia Foundation Scholarship
1996 – 1997	FIRC Fellowship in Molecular Oncology (Italian Foundation for Cancer Research)
1991 – 1995	Ph.D. Fellowship (Italian Ministry of Scientific Research)

Societies

American Society of Gene Therapy (ASGT)

American Society of Hematology (ASH)

American Society of Clinical Oncology (ASCO)

European Society of Medical Oncology (ESMO)

American Association for Cancer Research (AACR)

Editorial Activities

Ad hoc reviewer: Blood

Molecular Therapy

Human Gene Therapy

Journal of Gene Therapy

PUBLICATIONS

Selected Invited Presentations

EMBO Practical Course, Lentiviral Vectors for Gene Therapy, Turin 2000, "*Ex vivo gene transfer into Hematopoietic Stem Cells*"

ASGT 4th Annual Meeting, Seattle 2001, "*Gene Therapy of Fanconi Anemia by Lentiviral Vectors*"

Fanconi Anemia Symposium, Philadelphia 2002, "*Gene Therapy of Fanconi Anemia by Lentiviral Vectors*"

ASGT 8th Annual Meeting, St.Louis 2005, "*Regulation of Transgene Expression: Vector Designs and Applications*"

Immuno-oncology Frontiers, Miami 2018, *"Bispecific T-cell Engagers in Hematological Malignancies"*

4th Annual Immunotherapy in Myeloma Scientific Workshop, San Francisco 2018, *"Bispecific T-cell Engagers in Multiple Myeloma"*

4th Annual CAR-T Congress, Boston 2019, *"Bispecific Molecules in Hematological Malignancies"*

5th Annual Immunotherapy in Myeloma Scientific Workshop, Denver 2019, *"BCMA Bispecific Constructs in Multiple Myeloma"*

9th Whistler Global Summit on Hematological Malignancies, Whistler 2022, *"ADI-001: First-in-class Allogeneic Gamma Delta CD20 CAR T Cells in Non-Hodgkin's Lymphoma"*

3rd Gamma Delta T Therapies Summit, Boston 2022, *"Bringing a First-in-Class Allogeneic CAR-Engineered Gamma Delta T Cell Therapy to the Clinic"*

5th Gamma Delta T Therapies Summit, Boston 2024, *"Gamma Delta-based Cell Therapy in Cancer and Autoimmune Diseases"*

Full Papers and Reviews

Cellular and Molecular Biology of the Hepatocyte Growth Factor (1993 - 2001)

1. **Galimi, F.**, Brizzi, M.F., Comoglio, P.M. The hepatocyte growth factor and its receptor. Stem Cells. 1993;11 Suppl 2:22-30.

2. Giordano, S., Zhen, Z., Medico, E., Gaudino, G., **Galimi, F.**, Comoglio, P.M. Transfer of motogenic and invasive response to scatter factor/hepatocyte growth factor by transfection of human MET proto-oncogene. Proc Natl Acad Sci U S A. 1993;90:649-653.

3. Boccaccio, C., Gaudino, G., Gambarotta, G., **Galimi, F.**, Comoglio, P.M. Hepatocyte growth factor (HGF) receptor expression is inducible and is part of the delayed-early response to HGF. J Biol Chem. 1994;269:12846-12851.

4. **Galimi, F.**, Bagnara, G.P., Bonsi, L., Cottone, E., Follenzi, A., Simeone, A., Comoglio, P.M. Hepatocyte growth factor induces proliferation and differentiation of multipotent and erythroid hemopoietic progenitors. J Cell Biol. 1994;127:1743-1754.

5. Negro, F., Papotti, M., Pacchioni, D., **Galimi, F.**, Bonino, F., Bussolati, G. Detection of human androgen receptor mRNA in hepatocellular carcinoma by in situ hybridisation. Liver. 1994;14:213-219.

6. **Galimi, F.**, Comoglio, P.M. Control of invasive cell growth by the Met family oncogenes. In: Mihich, E., Hausman, D., eds. Cancer Genes: Functional Aspects. New York: Plenum Publishing Corporation; 1995.

7. Naldini, L., Vigna, E., Bardelli, A., Follenzi, A., **Galimi, F.**, Comoglio, P.M. Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction. J Biol Chem. 1995;270:603-611.

8. Grano, M., **Galimi, F.**, Zambonin, G., Colucci, S., Cottone, E., Zallone, A.Z., Comoglio, P.M. Hepatocyte growth factor is a coupling factor for osteoclasts and osteoblasts in vitro. Proc Natl Acad Sci U S A. 1996;93:7644-7648.

9. Graziani, A., **Galimi, F.**, Medico, E., Cottone, E., Gramaglia, D., Boccaccio, C., Comoglio, P.M. The HIV-1 nef protein interferes with phosphatidylinositol 3-kinase activation. J Biol Chem. 1996;271:6590-6593.

10. **Galimi, F.**, Cottone, E., Vigna, E., Arena, N., Boccaccio, C., Giordano, S., Naldini, L., Comoglio, P.M. Hepatocyte growth factor is a regulator of monocyte-macrophage function. J Immunol. 2001;166:1241-1247.

Lentiviral-mediated Gene Transfer Models of Human Disease (2002 - 2014)

11. **Galimi, F.**, Noll, M., Kanazawa, Y., Lax, T., Chen, C., Grompe, M., Verma, I.M. Gene therapy of Fanconi anemia: preclinical efficacy using lentiviral vectors. Blood. 2002;100:2732-2736.

12. **Galimi, F.**, Verma, I.M. Opportunities for the use of lentiviral vectors in human gene therapy. Curr Top Microbiol Immunol. 2002;261:245-254.

13. Beausejour, C.M., Krtolica, A., **Galimi, F.**, Narita, M., Lowe, S.W., Yaswen, P., Campisi, J. Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J. 2003;22:4212-4222.

14. Herzig, S., Hedrick, S., Morantte, I., Koo, S.H., **Galimi, F.**, Montminy, M. CREB controls hepatic lipid metabolism through nuclear hormone receptor PPAR-gamma. Nature. 2003;426:190-193.

15. Pastore, C., Picchio, G.R., **Galimi, F.**, Fish, R., Hartley, O., Offord, R.E., Mosier, D.E. Two mechanisms for human immunodeficiency virus type 1 inhibition by N-terminal modifications of RANTES. Antimicrob Agents Chemother. 2003;47:509-517.

16. Tiscornia, G., Tergaonkar, V., **Galimi, F.**, Verma, I.M. CRE recombinase-inducible RNA interference mediated by lentiviral vectors. Proc Natl Acad Sci U S A. 2004;101:7347-7351.

17. **Galimi, F.**, Saez, E., Gall, J., Hoong, N., Cho, G., Evans, R.M., Verma, I.M. Development of ecdysone-regulated lentiviral vectors. Mol Ther. 2005;11:142-148.

18. **Galimi, F.**, Summers, R.G., van Praag, H., Verma, I.M., Gage, F.H. A role for bone marrow-derived cells in the vasculature of non injured CNS. Blood. 2005;105:2400-2402.

19. Cantaluppi, V., Biancone, L., Romanazzi, G.M., Figliolini, F., Beltramo, S., Ninniri, M.S., **Galimi, F.**, Romagnoli, R., Franchello, A., Salizzoni, M., Perin, P.C., Ricordi, C., Segoloni, G.P., Camussi, G. Antiangiogenic and immunomodulatory effects of rapamycin on islet endothelium: relevance for islet transplantation. Am J Transplant. 2006;6:2601-2611.

20. Horky, L.L., **Galimi, F.**, Gage, F.H., Horner, P.J. Fate of endogenous stem/progenitor cells following spinal cord injury. J Comp Neurol. 2006;498:525-538.

21. Solinas, G., Naugler, W., **Galimi, F.**, Lee, M.S., Karin, M. Saturated fatty acids inhibit induction of insulin gene transcription by JNK-mediated phosphorylation of insulin-receptor substrates. Proc Natl Acad Sci U S A. 2006;103:16454-16459.

22. Sternsdorf, T., Phan, V.T., Maunakea, M.L., Ocampo, C.B., Sohal, J., Silletto, A., **Galimi, F.**, Le Beau, M.M., Evans, R.M., Kogan, S.C. Forced retinoic acid receptor alpha homodimers prime mice for APL-like leukemia. Cancer Cell. 2006;9:81-94.

23. Garcia-Rudaz, C., Luna, F., Tapia, V., Kerr, B., Colgin, L., **Galimi, F.**, Dissen, G.A., Rawlings, N.D., Ojeda, S.R. Fxna, a novel gene differentially expressed in the rat ovary at the time of folliculogenesis, is required for normal ovarian histogenesis. Development. 2007;134:945-957.

24. Maioli, M., Asara, Y., Pintus, A., Ninniri, S., Bettuzzi, S., Scaltriti, M., **Galimi, F.**, Ventura, C. Creating prodynorphin-expressing stem cells alerted for a high-throughput of cardiogenic commitment. Regen Med. 2007;2:193-202.

25. Heger, S., Mastronardi, C., Dissen, G.A., Lomniczi, A., Cabrera, R., Roth, C.L., Jung, H., **Galimi, F.**, Sippell, W., Ojeda, S.R. Enhanced at puberty 1 (EAP1) is a new transcriptional regulator of the female neuroendocrine reproductive axis. J Clin Invest. 2007;117:2145-2154.

26. Cantaluppi, V., Biancone, L., Romanazzi, G.M., Figliolini, F., Beltramo, S., **Galimi, F.**, Camboni, M.G., Deriu, E., Conaldi, P., Bottelli, A., Orlandi, V., Herrera, M.B., Pacitti, A., Segoloni, G.P., Camussi, G. Macrophage Stimulating Protein May Promote Tubular Regeneration after Acute Injury. J Am Soc Nephrol. 2008;19:1904-1918.

27. Dissen, G.A., Lomniczi, A., Neff, T.L., Hobbs, T.R., Kohama, S.G., Kroenke, C.D., **Galimi, F.**, Ojeda, S.R. In vivo manipulation of gene expression in non-human primates using lentiviral vectors as delivery vehicles. Methods. 2009;49:70-77.

28. Begemann, S., **Galimi, F.**, Karlseder, J. Moderate expression of TRF2 in the hematopoietic system increases development of large cell blastic T-cell lymphomas. Aging. 2009;1:122-130.

29. Colombino, M., Avallone, A., Izzo, F., Tatangelo, F., Budroni, M., Cossu, A., **Galimi, F.**, Comella, P., Botti, G., Sini, M.C., Palmieri, G. Molecular analysis of Fanconi anemia (FA) and mismatch repair (MMR) genes in patients with colorectal carcinoma. Oncol Rep. 2011; 25:899-904.

30. Dissen, G.A., McBride, J., Lomniczia, A., Matagnea, V., Dorfmana, M., Neffa, T.L., **Galimi, F.**, Ojeda, S.R. Using Lentiviral Vectors as Delivery Vehicles for Gene Therapy. In: Morozov, A., ed. Controlled Genetic Manipulations. Neuromethods, 2012, vol 65, pp 69-96. Humana Press, Totowa, NJ.

31. Cantaluppi, V., Biancone, L., Figliolini, F., Beltramo, S., Medica, D. Deregibusa, M.C., **Galimi, F.**, Romagnoli, R., Salizzoni, M., Tetta, C., Segoloni, G.P., Camussi, G. Microvesicles derived from endothelial progenitor cells enhance neoangiogenesis of transplanted human pancreatic islets. Cell Tranpl. 2012; 21:1305-20.

32. Lee, H.S., Ghetti, A., Pinto-Duarte, A., Wang, X., Dziewczapolski, G., **Galimi, F.**, Huitron-Resendiz, S., Pina-Crespo, J., Amanda J. Roberts, A.J., Verma, I.M., Sejnowski, T.J., Heinemann, S.F. Astrocytes contribute to gamma oscillations and recognition memory. Proc Natl Acad Sci U S A. 2014; 111:E3343-52.

33. Secchi, C., Carta, M., Crescio, C., Spano, A., Arras, M., Caocci, G., **Galimi, F.**, La Nasa, G., Pippia, P., Turrini, F., Pantaleo, A. T cell tyrosine phosphorylation response to transient redox stress. Cell Signal. 2015; 27:777-88.

Translational Medicine and Early Clinical Development (2012 - present)

34. Scagliotti, G.V., Vynnychenko, I., Park, K., Ichinose, Y., Kubota, K., Blackhall, F., Pirker, R., Galiulin, R., Ciuleanu, T., Sydorenko, O., Dediu, M., Papai-Szekely, Z., Martinez Banaclocha, N., McCoy, S., Yao, B., Hei, Y., **Galimi, F.**, Spigel, D.R., on behalf of the MONET1 Study Group. An International, Randomized, Placebo-Controlled, Double-Blind Phase III Study of Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer: MONET1. J Clin Oncol. 2012; 30:2829-36.

35. Kindler, H.L., Richards, D.A., Garbo, L.E., Garon, E.B., Stephenson, J.J., Rocha-Lima, C.M., Safran, H., Chan, D., Kocs, D.M., **Galimi, F.**, McGreivy, J., Bray, S.L., Hei, Y., Feigal, E.G., Loh, E., Fuchs, C.S. A Randomized, Placebo-Controlled Phase 2 Study of Ganitumab (AMG 479) or Conatumumab (AMG 655) in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer. Ann Oncol. 2012; 23:2834-42.

36. Paz-Ares, A., Bálint, B., de Boer, R.H., van Meerbeeck, J.P., Wierzbicki, R., De Souza, P., **Galimi, F.**, Haddad, V., Sabin, T., Hei, Y., Pan, Y., Cottrell, S., Hsu, C.P., Ramlau, R. A Randomized Phase 2 Study of Paclitaxel and Carboplatin With or Without Conatumumab for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. J Thor Oncol. 2013; 8:329-37.

37. Cohn, A.L., Tabernero, J., Maurel, J., Nowara, E., Sastre, J., Chuah, B.Y.S., Kopp, M.V., Sakaeva, D.D., Mitchell, E.P., Dubey, S., Suzuki, S., Hei, Y., **Galimi, F.**, McCaffery, I., Pan, Y., Loberg, R., Cottrell, S., Choo, S.P. A Randomized, Placebo-Controlled Phase 2 Study of Ganitumab or Conatumumab in Combination With FOLFIRI for Second-Line Treatment of Mutant KRAS Metastatic Colorectal Cancer. Ann Oncol. 2013; 24:1777-85.

38. Fuchs, C., Fakih, M., Schwartzberg, L., Cohn, A., Yee, L., Dreisbach, L., Kozloff, M.F., Hei, Y., **Galimi, F.**, Pan, Y., Haddad, V., Hsu C.P., Sabin A., Saltz, L. TRAIL Agonist Conatumumab Plus Modified FOLFOX6 and Bevacizumab for the First-line Treatment of Patients with Metastatic Colorectal Cancer: A Phase 1b/2 Clinical Trial. Cancer. 2013; 119:4290-8.

39. Tabernero, J., Chawla, S.P., Kindler, H., Reckamp, K., Chiorean, E.G., Azad, N.S., Lockhart, A.C., Hsu, C.P., Baker, N.F., **Galimi, F.**, Beltran, P., Baselga, J. Anti-cancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab. Targeted Oncology. 2015; 10:65-76.

40. Caocci, G., Greco, M., Delogu, G., Secchi, C., Perra, A., Ghiani, S., Orru, F., Vacca, A., **Galimi, F.**, La Nasa, G. Ruxolitinib therapy and telomere length in myelofibrosis. Blood Cancer J. 2016; 6:e479.

41. Caocci, G., Greco, M., Delogu, G., Secchi, C., Martino, B., Labate, C., Abruzzese, E., Trawinska, M.M., Galimberti, S., Orru, F., Fozza, C., Gambacorti Passerini, C., **Galimi, F.**, La Nasa, G. Telomere length shortening is associated with treatment-free remission in chronic myeloid leukemia patients. J Hematol Oncol. 2016; 9:63.

42. Secchi, C., Orecchioni, M., Carta, M., **Galimi, F.**, Turrini, F., Pantaleo, A. Signaling Response to Transient Redox Stress in Human Isolated T Cells: Molecular Sensor Role of Syk Kinase and Functional Involvement of IL2 Receptor and L-Selectin. Sensors (Basel). 2020; 20:466.

43. Svensson, M.N.D., Zoccheddu, M., Yang, S., Nygaard, G., Secchi, C., Doody, K.M., Slowikowski, K., Mizoguchi, F., Humby, F., Hands, R., Santelli, E., Sacchetti, C., Wakabayashi, K., Wu, D.J., Barback, C., Ai, R., Wang, W., Sims, G.P., Mydel, P., Kasama, T., Boyle, D.L., **Galimi, F.**, Vera, D., Tremblay, M.L., Raychaudhuri, S., Brenner, M.B., Firestein, G.S., Pitzalis, C., Ekwall, A.K.H., Stanford, S.M., Bottini, N.. Synoviocyte-targeted therapy synergizes with TNF inhibition in reversing arthritis. Sci Adv. 2020; 6:eaba4353.

44. Giordo, R., Nasrallah, G.K., Posadino, A.M., **Galimi, F.**, Capobianco, G., Eid, A.H., Pintus, G. Resveratrol-elicited PKC inhibition counteracts NOX-mediated endothelial to mesenchymal transition in human retinal endothelial cells exposed to high glucose. Antioxidants. 2021; 10: 224.